Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints

The precision medicine era in non-small cell lung cancer (NSCLC) was born with the identification of EGFR mutations and the possibility to treat patients harbouring EGFR alterations with specific and targeted tyrosine kinase inhibitors (1-3). Thinking about this progress today it seems to look at the prehistory of lung cancer treatment, but only about 10 years have passed in which we revolutionized the survival of our patients (4).